Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 7/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7899278 | 0.92 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1RAB9ABLM | |
| SCHEMBL2739418 | 0.87 | BLM (0.57) | KMT2AMEN1BLMKDM4EALDH1A1 | |
| SCHEMBL20756575 | 0.87 | BLM (0.57) | KMT2AMEN1BLMKDM4EALDH1A1 | |
| SCHEMBL180620 | 0.87 | — | — | |
| SCHEMBL8213345 | 0.84 | HSD11B1 (0.56) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL25701777 | 0.84 | HSD11B1 (0.53) | HSD11B1KDM4EALDH1A1 | |
| SCHEMBL24500534 | 0.82 | DRD3 (0.51) | KMT2AMEN1BLMALDH1A1DRD3 | |
| SCHEMBL229115 | 0.82 | ALDH1A1 (0.60) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL84384 | 0.82 | HSD11B1 (0.59) | HSD11B1KMT2AMEN1RAB9AKDM4E | |
| SCHEMBL22281655 | 0.82 | HSD11B1 (0.51) | HSD11B1KMT2AMEN1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| EP-3596072-B1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-06-22 | — | — | EP | disclosed |
| WO-2022090481-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | WO | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-01-20 | — | — | US | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-7553976-B2 | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) (FR) | 2009-06-30 | — | — | US | disclosed |
| US-20090163492-A1 | Substituted Oxindole Derivatives, Drugs Containing Said Derivatives and the Use Thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7459558-B2 | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-12-02 | — | — | US | disclosed |
| WO-2008106619-A2 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080182993-A1 | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS (S.C.R.A.S.) | 2008-07-31 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | AMBIT BIOSCIENCES CORPORATION | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | HSD11B1 1676/4885KMT2A 1835/4885MEN1 1241/4885 |
| US-20080182993-A1 | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them | ADRB2, ADRA2C, PNMT | HSD11B1 4260/4885KMT2A 1254/4885MEN1 1199/4885 |
| US-11655238-B2 | MMPL3 inhibitors, compositions and uses thereof | TIMP3, AFG3L2, MMP3 | HSD11B1 4031/4885KMT2A 4137/4885MEN1 1704/4885 |
| US-20220017492-A1 | MMPL3 INHIBITORS, COMPOSITIONS AND USES THEREOF | TIMP3, AFG3L2, MMP3 | HSD11B1 4031/4885KMT2A 4137/4885MEN1 1704/4885 |
| US-20100121049-A1 | INDENOISOQUINOLINONE ANALOGS AND METHODS OF USE THEREOF | TNNI3, IDH2, GLS | HSD11B1 1397/4885KMT2A 3200/4885MEN1 4008/4885 |
| US-20070232604-A1 | receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors | GRK2, GRK3, BLK | HSD11B1 4668/4885KMT2A 2024/4885MEN1 4104/4885 |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | HSD11B1 3254/4885KMT2A 323/4885MEN1 3623/4885 |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885KMT2A 3083/4885MEN1 3474/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | HSD11B1 1191/4885KMT2A 4156/4885MEN1 4052/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | HSD11B1 2374/4885KMT2A 1377/4885MEN1 1085/4885 |
| US-20090163492-A1 | Substituted Oxindole Derivatives, Drugs Containing Said Derivatives and the Use Thereof | OXTR, AVPR2, AVPR1B | HSD11B1 539/4885KMT2A 3756/4885MEN1 611/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | HSD11B1 1191/4885KMT2A 4156/4885MEN1 4052/4885 |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | HSD11B1 3558/4885KMT2A 395/4885MEN1 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.